The need to lower systolic blood pressure

Shrivastava, Sadhana; Kochar, Mahendr S.

doi:10.1007/s11906-000-0024-0

Cited by 4 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today there is mounting evidence that elevated systolic blood pressure is at least as important as elevated diastolic blood pressure as a cardiovascular risk factor [18]. Moreover, it has become clear that the control of systolic blood pressure also affords significant protection against major cardiovascular complications.…”

Section: The Need To Reach Target Blood Pressuresmentioning

confidence: 99%

Fixed low-dose combination therapy for hypertension

Waeber¹

2002

Curr Hypertens Rep

View full text Add to dashboard Cite

Despite the availability of various classes of antihypertensive agents that lower blood pressure by different primary actions, the treatment of hypertension remains a difficult task. Essential hypertension has a highly heterogeneous character, so that monotherapies are often not sufficient to normalize blood pressure. This is especially true since the goal of treatment is currently to normalize both systolic and diastolic blood pressure. By combining medications acting by different mechanisms, it is possible to gain considerably in terms of antihypertensive efficacy because of synergistic impacts on the cardiovascular system. Furthermore, low doses of antihypertensive agents are generally sufficient when used in combination, which accounts for the excellent tolerability of combination products. Fixed low-dose combinations are very useful tools for treating hypertensive patients. Because of their simplicity of use, and the fact that they improve the blood pressure response rate while minimizing the incidence of adverse effects, such combinations are increasingly being considered as suitable for both second-line and first-line therapy.

show abstract

Section: The Need To Reach Target Blood Pressuresmentioning

confidence: 99%

Fixed low-dose combination therapy for hypertension

Waeber¹

2002

Curr Hypertens Rep

View full text Add to dashboard Cite

show abstract

Trials in isolated systolic hypertension: An update

Waeber¹

2003

Curr Cardiol Rep

View full text Add to dashboard Cite

Isolated systolic hypertension (ISH) has proved to be a powerful predisposing factor for cardiovascular diseases in the elderly. Recent placebo-controlled interventional trials such as the Systolic Hypertension in the Elderly Program, the Systolic Hypertension in Europe, and the Systolic Hypertension in China showed that the lowering of systolic blood pressure using a diuretic- or a calcium antagonist-based treatment is associated with a decrease in cardiovascular events. Antihypertensive therapy was found especially effective in preventing stroke in the elderly with ISH. A slowing in the progression of dementia was observed in patients randomized to a calcium antagonist-based treatment. Patients at high cardiovascular risk such as those with diabetes benefited the most from treatment. In another trial performed in patients with left ventricular hypertrophy (Losartan Intervention For Endpoint Reduction), a subset of patients had ISH. In those patients, an angiotensin II antagonist-based treatment was superior to a b-blocker-based treatment in preventing cardiovascular complications. The experience accumulated in patients with ISH showed that combination therapy is often required to control blood pressure. Overall, the evidence available today indicates that pharmacologic treatment of ISH markedly improves the outcome of elderly patients.

show abstract

Trials in isolated systolic hypertension: An update

Waeber¹

2003

Current Science Inc

View full text Add to dashboard Cite

Isolated systolic hypertension (ISH) has proved to be a powerful predisposing factor for cardiovascular diseases in the elderly. Recent placebo-controlled interventional trials such as the Systolic Hypertension in the Elderly Program (SHEP), the Systolic Hypertension in Europe (Syst-Eur), and the Systolic Hypertension in China (Syst-China) showed that the lowering of systolic blood pressure using a diuretic- or a calcium antagonist-based treatment is associated with a decrease in cardiovascular events. Antihypertensive therapy was found especially effective in preventing stroke in the elderly with ISH. A slowing in the progression of dementia was observed in patients randomized to a calcium antagonist-based treatment. Patients at high cardiovascular risk such as those with diabetes benefited the most from treatment. In another trial performed in patients with left ventricular hypertrophy (Losartan Intervention For Endpoint Reduction ), a subset of patients had ISH. In those patients, an angiotensin II antagonist-based treatment was superior to a b-blocker-based treatment in preventing cardiovascular complications. The experience accumulated in patients with ISH showed that combination therapy is often required to control blood pressure. Overall, the evidence available today indicates that pharmacologic treatment of ISH markedly improves the outcome of elderly patients.

show abstract

The need to lower systolic blood pressure

Cited by 4 publications

References 39 publications

Fixed low-dose combination therapy for hypertension

Fixed low-dose combination therapy for hypertension

Trials in isolated systolic hypertension: An update

Trials in isolated systolic hypertension: An update

Contact Info

Product

Resources

About